These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12271597)

  • 41. [Treatment experience of patients with irritable bowel syndrome complicated by constipations with medicinal preparation softovak].
    Ruchkina IN; Lychkova AE; Parfenov AI
    Eksp Klin Gastroenterol; 2007; (5):103-6. PubMed ID: 18389606
    [No Abstract]   [Full Text] [Related]  

  • 42. Meta-analysis: The treatment of irritable bowel syndrome.
    Lesbros-Pantoflickova D; Michetti P; Fried M; Beglinger C; Blum AL
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1253-69. PubMed ID: 15606387
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Irritable bowel syndrome: new recommendations for diagnosis and treatment.
    Lacy BE
    Arch Intern Med; 2003 Jun; 163(11):1374-5. PubMed ID: 12796080
    [No Abstract]   [Full Text] [Related]  

  • 44. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
    Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H
    Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Irritable bowel syndrome: issues of diagnosis and treatment efficiency].
    Loranskaia ID
    Eksp Klin Gastroenterol; 2008; (1):90-5. PubMed ID: 19145859
    [No Abstract]   [Full Text] [Related]  

  • 46. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
    Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M
    Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Verapamil in the treatment of irritable bowel syndrome.
    Byrne S
    J Clin Psychiatry; 1987 Sep; 48(9):388. PubMed ID: 3624216
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome.
    Vahedi H; Merat S; Momtahen S; Kazzazi AS; Ghaffari N; Olfati G; Malekzadeh R
    Aliment Pharmacol Ther; 2008 Apr; 27(8):678-84. PubMed ID: 18248658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The synthetic leu-enkephalin--dalargin--in the therapy of the irritable bowel syndrome and chronic noninfectious undefined colitis].
    Smishchuk IuO
    Lik Sprava; 1998 Jun; (4):93-6. PubMed ID: 9784715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eziopitant. Pfizer.
    Evangelista S
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1441-3. PubMed ID: 11890362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
    Chang FY; Lu CL; Chen CY; Luo JC
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
    Funatsu T; Takeuchi A; Hirata T; Keto Y; Akuzawa S; Sasamata M
    Eur J Pharmacol; 2007 Nov; 573(1-3):190-5. PubMed ID: 17658508
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
    Reilly MC; Barghout V; McBurney CR; Niecko TE
    Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Irritable bowel syndrome: current therapeutic approach].
    Olmos J
    Acta Gastroenterol Latinoam; 1995; 25(3):183-4. PubMed ID: 8600706
    [No Abstract]   [Full Text] [Related]  

  • 55. [Use of hypothalamic phospholipid liposomes in patients with irritable bowel syndrome].
    Aguglia E; Di Cataldo A; Sapienza S; Urbano D; Latteri F
    Clin Ter; 1985 May; 113(3):205-9. PubMed ID: 4017499
    [No Abstract]   [Full Text] [Related]  

  • 56. Some of the challenges in drug development for irritable bowel syndrome.
    Mayer EA
    Gut; 2001 May; 48(5):585-6. PubMed ID: 11302947
    [No Abstract]   [Full Text] [Related]  

  • 57. A review of irritable bowel syndrome and an update on therapeutic approaches.
    Bassett JT; Cash BD
    Expert Opin Pharmacother; 2008 May; 9(7):1129-43. PubMed ID: 18422471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
    Avigan M; Justice R; Mackey AC; Nair N
    Am J Gastroenterol; 2003 Sep; 98(9):2105-6. PubMed ID: 14499800
    [No Abstract]   [Full Text] [Related]  

  • 59. [Tegaserod in treatment of women with irritable bowel syndrome].
    Munck LK; Ainsworth MA
    Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patients with irritable bowel syndrome in primary care appear not to be heavy healthcare utilizers.
    Faresjö A; Grodzinsky E; Foldevi M; Johansson S; Wallander MA
    Aliment Pharmacol Ther; 2006 Mar; 23(6):807-14. PubMed ID: 16556183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.